Immune Pharmacy`s Business Development priorities are:

  1. The in-licensing or co-development of clinical stage Monoclonal Antibodies for targeted indications with high unmet medical need in oncology.
  2. The in-licensing or co-development of highly innovative Early Development Candidate Monoclonal Antibodies, with potential to reach Clinical Stage within 18-24 months.
  3. Co development of NanomAbs, second generation antibody drug conjugates, using immune proprietary antibodies or partner targeting ligands.

Business Development

To initiate the dialogue with Immune Canadian pharmacy, please request contact with Anna Baran, Director of Corporate Development, through the Contact Us page.